Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

NBE Therapeutics AG

NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADC™) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display™ technology for antibody discovery, its SMAC-Technology™ for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform. The company is financially backed by the Boehringer Ingelheim Venture Fund (D), the PPF Group and Novo Holdings (DK) as institutional investors, and by additional Swiss, German and Dutch private investors. *


Period Start 2012-01-01 established
Product Industry antibody-drug conjugate (ADC)
Persons Person Grawunder, Ulf (NBE Therapeutics 202008– COO + CDO before CEO + Founder before 4-Antibody CSO)
  Person 2 Schlick, Erich (Wellington Partners 201009 before 3i Healthcare Deutschland 200403)
Region Region Basel BS
  Country Switzerland
  Street 60c Hochbergerstr.
Technology Park Basel
  City 4057 Basel
  Tel +41-61-633-2230
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: NBE Therapeutics AG. (8/3/20). "Press Release: NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer". Basel.
Record changed: 2020-12-13


Picture [iito] Plain Stupid Simple 650x80px

More documents for NBE Therapeutics AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top